Novo/Catalent: Buyer Negotiating Contract Extensions with Complaining Drugmakers
Novo Holdings is negotiating contract extensions with drugmakers complaining to antitrust enforcers about its proposed $16.5 billion acquisition of pharmaceutical contract manufacturer Catalent...
Dec 03, 2024
Read Now >